Cancer Therapeutics and Biotherapeutics Market Size, Share and Trends 2026 to 2035
Cancer Therapeutics and Biotherapeutics Market (By Application: Blood Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Breast Cancer, Cervical Cancer, Head and Neck Cancer, Giloblastoma, Malignant Meningioma, Mesothelioma, Melanoma, Others; By Top Selling Drugs: Revlimid, Avastin, Herceptin, Rituxan, OPDIVO, Gleevec, Velcade, Imbruvica, Ibrance, Zytiga, Alimta, Xtandi, Tarceva, Perjeta, Termodar, Others; By Product Type: Chemotherapy, Radiation Therapy, Hormone Therapy, Biotherapy, Others; By End User: Consumption (Sales), Household, Hospital) - Global Industry Analysis, Size, Trends, Leading Companies, Regional Outlook, and Forecast 2026 to 2035
Get a Sample
Table Of Content
What is the Cancer Therapeutics and Biotherapeutics Market Size?
The global cancer therapeutics and biotherapeutics market size accounted for USD 210.73 billion in 2025 and is expected to exceed around USD 475.26 billion by 2035, growing at a CAGR of 8.47% from 2026 to 2035. The key players operating in the market are focused on adopting inorganic growth strategies like acquisition and merger to develop cancer therapeutics and biotherapeutics which is estimated to drive the global cancer therapeutics and biotherapeutics market over the forecast period.
Cancer Therapeutics and Biotherapeutics Market Key Takeaways
- North America dominated the global market with the largest market share of 41% in 2025.
- Asia Pacific is projected to expand at the notable CAGR during the forecast period.
- By application, the lung cancer segment contributed the highest market share in 2025.
- By application, the head and neck cancer segments is estimated to be the fastest-growing segment during the forecast period.
- By top selling drugs, the revlimid segment has held the largest market share in 2025.
- By top selling drugs, the zytiga segments is predicted to be the fastest-growing segment during the forecast period.
How Can AI Improve Cancer Therapeutics?
The integration of artificial intelligence assists in drug discovery and development. AI assists in analyzing large datasets to identify potential drug candidates, predict their efficacy, and optimize drug design, significantly reducing the time and cost associated with traditional drug discovery processes. AI algorithms helps in analyzing patient data, including genetic information, to develop personalized treatment plans. This approach ensures that patients receive therapies tailored to their specific genetic makeup and cancer type, improving treatment outcomes.
AI-powered chatbots and virtual assistants has ability to provide patients with information, support, and reminders about their treatment plans, improving adherence and overall patient experience. By automating complex tasks and enhancing decision-making processes, AI can help reduce the costs associated with drug development, clinical trials, and patient care.
U.S. Cancer Therapeutics and Biotherapeutics Market Size and Growth 2026 to 2035
The U.S. cancer therapeutics and biotherapeutics market size was evaluated at USD 60.48 billion in 2025 and is projected to be worth around USD 139.15 billion by 2035, growing at a CAGR of 8.69% from 2026 to 2035.
North America dominated the cancer therapeutics and biotherapeutics market in 2025. The presence of vast number of market players is driving the growth of the cancer therapeutics and biotherapeutics market. Another factor driving the growth of the cancer therapeutics and biotherapeutics market in North America region is growing prevalence of cancers such as breast cancer, prostate cancer, and lung cancer.
Asia-Pacific, on the other hand, is expected to develop at the fastest rate during the forecast period. China and Indiadominate the cancer therapeutics and biotherapeutics market in Asia-Pacific region. The cancer therapeutics and biotherapeutics market in Asia-Pacific region is growing due to the growing awareness about the cancer in countries such as India, China, South Korea, and Japan. The government of these countries is highly investing in research and development activities. In addition, the growing geriatric population is also boosting the growth of the cancer therapeutics and biotherapeutics market in the region during the forecast period.
Rising government initiatives in India for launching cancer therapeutics has driven the market in Asia Pacific region. For instance, in April, 2024, The President, speaking at the event, declared that the introduction of India's first gene treatment represents a significant advancement in the fight against cancer. The availability and affordability of this treatment option, known as "CAR-T cell therapy," offers humanity as a whole fresh hope. She said she was confident it would be successful in providing many patients new lives. According to the President, CAR-T cell treatment is regarded as one of the most amazing developments in medical research. Although it has long been accessible in industrialized countries, the majority of patients worldwide cannot afford it due to its high cost.
According to the President, IT Bombay is well-known as a model for technology education both in India and internationally. In addition to using technology for the benefit of humanity, CAR-T cell therapy development has involved collaborations with industry and a renowned institution in a different subject. The emphasis that IT Bombay has placed on research and development over the past thirty years has made this feasible. The president claimed that India as a whole would gain a great deal from the current technology revolution thanks to the expertise and abilities of the teachers and students at IT Bombay and other comparable institutes.
Cancer Therapeutics and Biotherapeutics Market Growth Factors
- Increasing number of regulatory approvals for new cancer drugs and therapies enhances cancer therapeutics and biotherapeutics market expansion.
- Advances in diagnostic technologies enable earlier detection of cancer, increasing the need for effective therapeutic options, which has driven the market growth.
- The shift towards tailored treatments based on genetic and molecular profiles of patients is driving the development and adoption of targeted therapies.
- Strategic collaborations between biotech firms, research institutions, and pharmaceutical companies are fostering innovation and accelerating the development of new cancer treatments.
- Increased awareness about cancer and the availability of treatment options, along with advocacy for better healthcare access, are contributing to cancer therapeutics and biotherapeutics market growth.
- Growing healthcare spending in both developed and emerging economies supports the adoption of advanced cancer therapies.
Market Scope
| Report Coverage | Details |
| Market Size in 2025 | USD 210.73 Billion |
| Market Size in 2035 | USD 475.26 Billion |
| Market Growth Rate from 2026 to 2035 | CAGR of 8.47% |
| Largest Market | North America |
| Fastest Growing Market | Asia Pacific |
| Base Year | 2025 |
| Forecast Period | 2026 to 2035 |
| Segments Covered | Application, Top Selling Drugs, End User, Product, Geography |
| Regions Covered | North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa |
The favorable government regulations and guidelines for the treatment of cancer is driving the growth of the global cancer therapeutics and biotherapeutics market. The number of drug manufacturers is involved in the manufacturing process of cancer therapeutics and biotherapeutics. The key market players are constantly adopting the marketing strategies for the growth and development of cancer therapeutics and biotherapeutics market.
Nowadays, the approvals on the drugs and medications by Food and Drug Administration (FDA) are quite easy. This factor is encouraging market players to develop new products in the cancer therapeutics and biotherapeutics market. Moreover, the market players are collaborating with logistics companies for supplying drugs and medicines on an international level. This factor is supporting the growth of the global cancer therapeutics and biotherapeutics market over the forecast period.
Application Insights
The lung cancer segment dominated the cancer therapeutics and biotherapeutics market in 2025. The lung cancer is the most common cancer killer, accounting for about a quarter of all cancer fatalities. The lung cancer kills more people than breast cancer, colon cancer, and prostate cancer combined every year. Thus, the lung cancer segment is growing at a rapid pace.
The head and neck cancer segment is fastest growing segment of the cancer therapeutics and biotherapeutics market in 2022. The rising incidences of cancer are driving the segment growth. In the U.S., head and neck cancer accounts for around 4% of all cancers. Thus, this factor is driving the growth of the segment over the projected period.
Top Selling Drugs Insights
The Revlimid segment dominated the cancer therapeutics and biotherapeutics market in 2025. The Revlimid is used in the treatment of wide range of cancers. This drug helps to increase the life expectancy rate of cancer patients. In addition, Revlimid contains lenalidomide, which treat myeloma and myelodysplastic syndrome. As a result, the growing prevalence of cancer disorders is driving the growth of the segment.
The Zytiga segment is fastest growing segment of the cancer therapeutics and biotherapeutics market in 2022. Zytiga contains abiraterone acetate which is mainly used in the treatment of the prostate cancer. This drug is approved by Food and Drug Administration (FDA). The doctors recommend to avoid overdoses of Zytiga. This can also lead to death and fatalities.
Key Developments
- In September, 2024, Oracle, computer software company revealed the Trends in CancerMPact Treatment Architecture. With the use of the new cloud-based tool, pharmaceutical companies can now examine global and historical patterns of cancer treatment to assess the effects of market events, including the approval of new drugs, and the adoption of drugs and therapeutic classes. The newest module in CancerMPact, a thorough oncology decision assistance tool, is called Treatment Architecture Trends. It can be applied to strategic planning, market sizing and analysis, and the discovery of business prospects in the US, Europe, Japan, and China. The cloud-based integrated Future Trends and Insights, CancerLandscape, and Treatment Architecture modules are also part of the CancerMPact platform.
- In January, 2025, according to Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") and its oncology-focused subsidiary, Citius Oncology significant progress has been made in getting ready for the commercial launch of LYMPHIR, an innovative immunotherapy for the treatment of adults with relapsed or refractory cutaneous T-cell lymphoma (CTCL). With plans to introduce LYMPHIR in the first half of 2025, management is committed to providing patients with access to the medication as soon as possible.
Cancer Therapeutics and Biotherapeutics Market Companies
- Amgen Inc.
- Bristol-Myers Squibb
- Celgene Corporation
- ELI Lilly and Company
- Hoffmann-La Roche AG
- EnGeneIC Ltd
- Merck & Co Inc.
- Novartis
- Pfizer Inc.
- Johnson & Johnson
Key Developments
- In September, 2024, Oracle, computer software company revealed the Trends in CancerMPact Treatment Architecture. With the use of the new cloud-based tool, pharmaceutical companies can now examine global and historical patterns of cancer treatment to assess the effects of market events, including the approval of new drugs, and the adoption of drugs and therapeutic classes. The newest module in CancerMPact, a thorough oncology decision assistance tool, is called Treatment Architecture Trends. It can be applied to strategic planning, market sizing and analysis, and the discovery of business prospects in the US, Europe, Japan, and China. The cloud-based integrated Future Trends and Insights, CancerLandscape, and Treatment Architecture modules are also part of the CancerMPact platform.
- In January, 2025, according to Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") and its oncology-focused subsidiary, Citius Oncology significant progress has been made in getting ready for the commercial launch of LYMPHIR, an innovative immunotherapy for the treatment of adults with relapsed or refractory cutaneous T-cell lymphoma (CTCL). With plans to introduce LYMPHIR in the first half of 2025, management is committed to providing patients with access to the medication as soon as possible.
Segments Covered in the Report
By Application
- Blood Cancer
- Lung Cancer
- Colorectal Cancer
- Prostate Cancer
- Breast Cancer
- Cervical Cancer
- Head and Neck Cancer
- Giloblastoma
- Malignant Meningioma
- Mesothelioma
- Melanoma
- Others
By Top Selling Drugs
- Revlimid
- Avastin
- Herceptin
- Rituxan
- Opdivo
- Gleevec
- Velcade
- Imbruvica
- Ibrance
- Zytiga
- Alimta
- Xtandi
- Tarceva
- Perjeta
- Termodar
- Others
By Product Type
- Chemotherapy
- Radiation Therapy
- Hormone Therapy
- Biotherapy
- Others
By End User
- Consumption (Sales)
- Household
- Hospital
By Geography
- North America
- U.S.
- Canada
- Europe
- U.K.
- Germany
- France
- Asia-Pacific
- China
- India
- Japan
- South Korea
- Malaysia
- Philippines
- Latin America
- Brazil
- Rest of Latin America
- Middle East & Africa (MEA)
- GCC
- North Africa
- South Africa
- Rest of the Middle East & Africa
For inquiries regarding discounts, bulk purchases, or customization requests, please contact us at sales@precedenceresearch.com
Frequently Asked Questions
Ask For Sample
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
.webp)
sales@precedenceresearch.com
+1 804-441-9344
Schedule a Meeting
